Ipsen stock declines nearly 3%, among the laggards in the SBF 120
The biopharmaceutical laboratory's share is declining sharply at the end of the week, while the SBF 120 remains nearly stable during the session. This decline brings Ipsen back to technical levels to monitor, despite a balance sheet that remains very positive over longer horizons.
A decline of 2.61% that brings the share closer to its recently failed resistance at 169.20 €
Ipsen loses 2.61% to 164.20 € during the session, significantly underperforming a SBF 120 with limited decline of 0.33%. Ranked 112th out of 120 index members, the share is among the strongest declines in the SBF 120 this Friday. This movement follows a similar decline of nearly 3% last week, itself following a failure below the 169.20 € resistance level, a level that the price has been testing again without being able to breach it for several sessions.
The weekly decline stands at nearly 3%, but the share maintains a gain of 7.25% over the past month and nearly 40% over one year, which puts the decline into perspective over a longer timeframe. The VIX, which has fallen to 14.03 (against 15.20 the previous day), signals a globally calm market: Ipsen's decline is therefore specific to the share, not driven by macro concerns.
Moving averages still favorable despite selling pressure from the session
On the technical indicators front, the share remains above its three main moving averages. The 20-day MA at 162.43 € and the 50-day MA at 162.66 € serve as the first support, with the price approximately 1% above them. The 200-day MA is further away, at 151.07 €, representing a gap of 8.69% below the current price.
The RSI at 57 remains in neutral territory, with no oversold signal, indicating that today's selling pressure has not yet exhausted the medium-term bullish momentum. In parallel, the acquisition of Kartos Therapeutics finalized on August 24 has enriched Ipsen's portfolio with an experimental treatment for myelofibrosis (navtemadlin, in phase III), strengthening pipeline visibility without immediate impact on the share price. The resistance level of 169.20 € remains the level to breach for the share to regain bullish momentum; should the decline continue, the support of 153.10 € represents the next reference zone.
